NGIN is the acronym of an European research project entitled: “Next Generation HIV-1 Immunogens inducing broadly reactive Neutralising antibodies”. It is a collaborative, large-scale integrating project funded by the European Commission within the Seventh Framework Programme (FP7) for Research and Technological Development in the Cooperation programme and Health theme. It started on Feb. 1st 2008 and will continue for four years.
NGIN is an international consortium composed of 15 Institutions located in 8 different European countries: Belgium, Denmark, France, Italy, the Netherlands, Sweden, Switzerland, and the United Kingdom. The consortium members are collectively involved in novel and innovative scientific approaches aimed at the development of an HIV-1 vaccine. NGIN has as a goal the development of “next-generation” HIV-1 envelope-based immunogens that in combination with new adjuvant formulations are capable of eliciting high-titre, broadly reactive neutralising antibody responses. NGIN gathers the skills and efforts of many active European research groups operating in clinical, translational and experimental HIV-1/SIV research which will evaluate novel HIV-1 immunogens in small animal models and non-human primates. Successful formulations will be made available for proof-of-principle testing in humans.

Less Info